首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021–22: a cross-sectional study 2021- 2022年维多利亚州COVID-19疫苗相关心肌炎的临床表型:一项横断面研究
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-10 DOI: 10.5694/mja2.52557
Julia Smith, Silja Schrader, Hannah Morgan, Priya Shenton, Annette Alafaci, Nicholas Cox, Andrew J Taylor, James Hare, Bryn Jones, Nigel W Crawford, Jim P Buttery, Hazel J Clothier, Daryl R Cheng
<div> <section> <h3> Objectives</h3> <p>To describe myocarditis as an adverse event after coronavirus disease 2019 (COVID-19) vaccination, including a detailed description of clinical phenotypes and diagnostic test results and differences by age, sex, and degree of troponin level elevation.</p> </section> <section> <h3> Study design</h3> <p>Retrospective cross-sectional study.</p> </section> <section> <h3> Setting, participants</h3> <p>Cases of suspected myocarditis following the administration of a COVID-19 vaccine in Victoria during 22 February 2021 – 30 September 2022 reported to Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), with symptom onset within 14 days of vaccination, and deemed to be confirmed myocarditis according to the Brighton Collaboration Criteria.</p> </section> <section> <h3> Main outcome measures</h3> <p>Demographic (sex, broad age group), vaccine, and clinical presentation characteristics; cardiac investigation results (troponin levels, electrocardiography, echocardiography, cardiac magnetic resonance imaging [cMRI]).</p> </section> <section> <h3> Results</h3> <p>Of 454 SAEFVIC reports of suspected COVID-19 vaccine-associated myocarditis, 206 were deemed confirmed cases. The median age of people with confirmed myocarditis was 21 years (interquartile range [IQR], 16–32 years; range, 10–76 years); 129 were aged 24 years or younger (63%), 155 were male (75%). The median time from vaccination to symptom onset was two days (IQR, 1–4 days); 201 cases (98%) followed the administration of mRNA vaccines; five cases followed vaccination with AZD122. Forty-six cases followed first vaccine doses (22%), 138 second doses (67%), and 22 cases third vaccine doses (11.0%). In 201 cases, people initially presented to emergency departments; 129 people were admitted to hospital (63%; median length of stay, two days; IQR, 1–3 days). Five people were admitted to intensive care. Echocardiographic abnormalities were identified in 26 of 200 patients (13%); electrocardiographic abnormalities were identified in 105 of 206 patients (51%; less frequently in female than male patients: adjusted odds ratio, 0.75; 95% confidence interval, 0.64–0.89). Troponin levels were elevated in 205 of 206 patients; the median increase was greater in male (95.3-fold; IQR, 5.8–273-fold) than female patients (9.9-fold; IQR, 4.7–50-fold). No cMRI abnormalities were found in patients for whom the troponin increase was threefold or less.</p>
目的研究设计:回顾性横断面研究:回顾性横断面研究:2021年2月22日至2022年9月30日期间在维多利亚州接种COVID-19疫苗后疑似心肌炎的病例,接种后14天内出现症状,并根据布莱顿合作标准被认为确诊为心肌炎:人口统计学特征(性别、广泛年龄组)、疫苗和临床表现特征;心脏检查结果(肌钙蛋白水平、心电图、超声心动图、心脏磁共振成像 [cMRI]):在SAEFVIC报告的454例疑似COVID-19疫苗相关心肌炎病例中,有206例被认为是确诊病例。确诊心肌炎患者的中位年龄为21岁(四分位距[IQR],16-32岁;范围,10-76岁);129人年龄在24岁或以下(63%),155人为男性(75%)。从接种疫苗到症状出现的中位时间为两天(IQR,1-4 天);201 例(98%)接种了 mRNA 疫苗;5 例接种了 AZD122。46例接种了第一剂疫苗(22%),138例接种了第二剂疫苗(67%),22例接种了第三剂疫苗(11.0%)。在201例病例中,最初就诊于急诊科;129人入院治疗(占63%;住院时间中位数为2天;IQR为1-3天)。5人被送入重症监护室。200 名患者中有 26 人(13%)发现超声心动图异常;206 名患者中有 105 人(51%)发现心电图异常;女性患者比男性患者少见:调整后的几率比为 0.75;95% 置信区间为 0.64-0.89。206 名患者中有 205 名患者肌钙蛋白水平升高;男性患者(95.3 倍;IQR,5.8-273 倍)升高的中位数高于女性患者(9.9 倍;IQR,4.7-50 倍)。肌钙蛋白升高3倍或以下的患者未发现cMRI异常:结论:在维多利亚州,COVID-19疫苗相关心肌炎的临床严重程度一般较轻。男性患者和年龄在 24 岁或以下的患者中更常出现较严重表型的标志物。肌钙蛋白升高三倍可作为对COVID-19疫苗相关性心肌炎患者进行风险分层的阈值,尤其是在cMRI设施有限的医院。
{"title":"Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021–22: a cross-sectional study","authors":"Julia Smith,&nbsp;Silja Schrader,&nbsp;Hannah Morgan,&nbsp;Priya Shenton,&nbsp;Annette Alafaci,&nbsp;Nicholas Cox,&nbsp;Andrew J Taylor,&nbsp;James Hare,&nbsp;Bryn Jones,&nbsp;Nigel W Crawford,&nbsp;Jim P Buttery,&nbsp;Hazel J Clothier,&nbsp;Daryl R Cheng","doi":"10.5694/mja2.52557","DOIUrl":"10.5694/mja2.52557","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To describe myocarditis as an adverse event after coronavirus disease 2019 (COVID-19) vaccination, including a detailed description of clinical phenotypes and diagnostic test results and differences by age, sex, and degree of troponin level elevation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective cross-sectional study.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cases of suspected myocarditis following the administration of a COVID-19 vaccine in Victoria during 22 February 2021 – 30 September 2022 reported to Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), with symptom onset within 14 days of vaccination, and deemed to be confirmed myocarditis according to the Brighton Collaboration Criteria.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcome measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Demographic (sex, broad age group), vaccine, and clinical presentation characteristics; cardiac investigation results (troponin levels, electrocardiography, echocardiography, cardiac magnetic resonance imaging [cMRI]).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 454 SAEFVIC reports of suspected COVID-19 vaccine-associated myocarditis, 206 were deemed confirmed cases. The median age of people with confirmed myocarditis was 21 years (interquartile range [IQR], 16–32 years; range, 10–76 years); 129 were aged 24 years or younger (63%), 155 were male (75%). The median time from vaccination to symptom onset was two days (IQR, 1–4 days); 201 cases (98%) followed the administration of mRNA vaccines; five cases followed vaccination with AZD122. Forty-six cases followed first vaccine doses (22%), 138 second doses (67%), and 22 cases third vaccine doses (11.0%). In 201 cases, people initially presented to emergency departments; 129 people were admitted to hospital (63%; median length of stay, two days; IQR, 1–3 days). Five people were admitted to intensive care. Echocardiographic abnormalities were identified in 26 of 200 patients (13%); electrocardiographic abnormalities were identified in 105 of 206 patients (51%; less frequently in female than male patients: adjusted odds ratio, 0.75; 95% confidence interval, 0.64–0.89). Troponin levels were elevated in 205 of 206 patients; the median increase was greater in male (95.3-fold; IQR, 5.8–273-fold) than female patients (9.9-fold; IQR, 4.7–50-fold). No cMRI abnormalities were found in patients for whom the troponin increase was threefold or less.&lt;/p&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 1","pages":"23-29"},"PeriodicalIF":6.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52557","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge about COVID-19 vaccines among Aboriginal and Torres Strait Islander people, and attitudes to and behaviours regarding COVID-19 and influenza vaccination: a survey 土著人和托雷斯海峡岛民对COVID-19疫苗的知识以及对COVID-19和流感疫苗接种的态度和行为的调查
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-10 DOI: 10.5694/mja2.52551
Shea Spierings, Victor M Oguoma, Anthony Shakeshaft, Jim Walker, Maree Toombs, James S Ward

Objectives

To assess Aboriginal and Torres Strait Islander people's knowledge about coronavirus disease 2019 (COVID-19) vaccines, and their attitudes to and behaviours regarding COVID-19 and influenza vaccinations.

Study design

Web-based survey.

Setting

Australia (excluding the Northern Territory), 1 October 2021 to 31 May 2022.

Participants

Convenience sample of Aboriginal and Torres Strait Islander people aged 16 years or older living in Australia.

Main outcome measures

Proportions of respondents who reported knowledge about COVID-19 vaccines, and attitudes to and behaviours regarding COVID-19 and influenza vaccinations.

Results

A total of 530 people provided valid survey responses; their median age was 27 years (interquartile range, 23–38 years), 255 (48%) were from urban areas, and 309 (58%) were men. Of the 480 participants (91%) who provided complete survey questions (including sex and location information), larger proportion of men than women believed COVID-19 vaccines were very or extremely trustworthy (219, 79% v 124, 61%) and very or extremely effective (212, 76% v 138, 68%). The prevalence of COVID-19 vaccination was lower among respondents aged 60 years or older than among those aged 16–29 years (adjusted prevalence ration [PR], 0.81; 95% confidence interval [CI], 0.66–0.99). After adjusting for socio-demographic factors, the association between intention to receive the influenza vaccine and receiving the COVID-19 vaccine was statistically significant (adjusted PR, 1.18; 95% CI, 1.09–1.27).

Conclusion

The high levels of trust in COVID-19 vaccines and their effectiveness indicate that Aboriginal and Torres Strait Islander people are confident about their safety and efficacy and understand the importance of vaccination. The findings also highlight a positive attitude to vaccination and a commitment to preventive health measures among Aboriginal and Torres Strait Islander people.

目的:了解原住民和托雷斯海峡岛民对2019冠状病毒病(COVID-19)疫苗的认知情况,以及对2019冠状病毒病和流感疫苗接种的态度和行为。研究设计:基于网络的调查。地点:澳大利亚(不包括北领地),2021年10月1日至2022年5月31日。参与者:居住在澳大利亚的16岁或以上的土著和托雷斯海峡岛民的方便样本。主要结局指标:报告COVID-19疫苗知识的受访者比例,以及对COVID-19和流感疫苗接种的态度和行为。结果:共有530人提供了有效的调查反馈;他们的年龄中位数为27岁(四分位数间距为23-38岁),255人(48%)来自城市地区,309人(58%)是男性。在提供完整调查问题(包括性别和位置信息)的480名参与者(91%)中,认为COVID-19疫苗非常或非常值得信赖(219人,79%对124人,61%)和非常或非常有效(212人,76%对138人,68%)的男性比例高于女性。60岁及以上受访者的COVID-19疫苗接种率低于16-29岁受访者(调整患病率[PR], 0.81;95%可信区间[CI], 0.66-0.99)。在对社会人口因素进行调整后,接种流感疫苗的意愿与接种COVID-19疫苗之间的相关性具有统计学意义(调整后的PR为1.18;95% ci, 1.09-1.27)。结论:对COVID-19疫苗及其有效性的高度信任表明原住民和托雷斯海峡岛民对其安全性和有效性充满信心,并了解疫苗接种的重要性。调查结果还突出表明,土著人和托雷斯海峡岛民对接种疫苗持积极态度,并承诺采取预防保健措施。
{"title":"Knowledge about COVID-19 vaccines among Aboriginal and Torres Strait Islander people, and attitudes to and behaviours regarding COVID-19 and influenza vaccination: a survey","authors":"Shea Spierings,&nbsp;Victor M Oguoma,&nbsp;Anthony Shakeshaft,&nbsp;Jim Walker,&nbsp;Maree Toombs,&nbsp;James S Ward","doi":"10.5694/mja2.52551","DOIUrl":"10.5694/mja2.52551","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess Aboriginal and Torres Strait Islander people's knowledge about coronavirus disease 2019 (COVID-19) vaccines, and their attitudes to and behaviours regarding COVID-19 and influenza vaccinations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study design</h3>\u0000 \u0000 <p>Web-based survey.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting</h3>\u0000 \u0000 <p>Australia (excluding the Northern Territory), 1 October 2021 to 31 May 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Participants</h3>\u0000 \u0000 <p>Convenience sample of Aboriginal and Torres Strait Islander people aged 16 years or older living in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main outcome measures</h3>\u0000 \u0000 <p>Proportions of respondents who reported knowledge about COVID-19 vaccines, and attitudes to and behaviours regarding COVID-19 and influenza vaccinations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 530 people provided valid survey responses; their median age was 27 years (interquartile range, 23–38 years), 255 (48%) were from urban areas, and 309 (58%) were men. Of the 480 participants (91%) who provided complete survey questions (including sex and location information), larger proportion of men than women believed COVID-19 vaccines were very or extremely trustworthy (219, 79% <i>v</i> 124, 61%) and very or extremely effective (212, 76% <i>v</i> 138, 68%). The prevalence of COVID-19 vaccination was lower among respondents aged 60 years or older than among those aged 16–29 years (adjusted prevalence ration [PR], 0.81; 95% confidence interval [CI], 0.66–0.99). After adjusting for socio-demographic factors, the association between intention to receive the influenza vaccine and receiving the COVID-19 vaccine was statistically significant (adjusted PR, 1.18; 95% CI, 1.09–1.27).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The high levels of trust in COVID-19 vaccines and their effectiveness indicate that Aboriginal and Torres Strait Islander people are confident about their safety and efficacy and understand the importance of vaccination. The findings also highlight a positive attitude to vaccination and a commitment to preventive health measures among Aboriginal and Torres Strait Islander people.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 1","pages":"30-37"},"PeriodicalIF":6.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged SARS-CoV-2 shedding in a lung transplant recipient: time for flexibility in infection prevention? 肺移植受者持续的SARS-CoV-2脱落:预防感染的灵活性时间?
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-10 DOI: 10.5694/mja2.52556
Alyssa Pradhan, David Pham, Alexander Brennan, Jen Kok, Priya Garg
<p>A 39-year-old woman underwent bilateral sequential lung transplantation for fibrotic hypersensitivity pneumonitis in May 2022. Her immunosuppression treatment included prednisolone, tacrolimus and mycophenolate. She received one dose of Comirnaty (Pfizer) pre-transplant and tixagevimab–cilgavimab in June 2022.</p><p>Her first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed on 14 December 2022 and she was treated with molnupiravir for five days. On Day 11 of illness, she presented to hospital in respiratory distress with hypoxia (SpO2; 73% on room air). SARS-CoV-2 RNA was detected by polymerase chain reaction (PCR) with a cycle threshold of 21.8 (cobas SARS-CoV-2 and Influenza A/B, Roche). A chest computed tomography scan demonstrated extensive bilateral ground-glass opacification (Box 1). She required intensive care unit admission for high-flow nasal oxygen (FiO<sub>2</sub> 60%, flow rate 50 litres) and received tocilizumab, ten days of remdesivir, increased prednisolone, and piperacillin–tazobactam. Three days of pulsed methylprednisolone was prescribed for possible transplant rejection. Despite clinical improvement, SARS-CoV-2 RNA remained detectable with a cycle threshold of 16.2 (VIASURE SARS-CoV-2, flu and RSV, Certest Biotec) and SARS-CoV-2 was isolated from a cell culture.<span><sup>1</sup></span> Whole genome sequencing identified Omicron BR.2 (variant of concern B.1.1.529) lineage, with molnupiravir-associated mutational signatures,<span><sup>2</sup></span> (sequence available on GISAID [Global Initiative of Sharing All Influenza Data]; 26/12/22: hCoV-19/Australia/NSW_ICPMR_40135/2022 and 03/03/23: hCoV-19/Australia/NSW_ICPMR_43136/2023).</p><p>The patient was transferred to a high acuity respiratory ward after three weeks, but over the ensuing six weeks, became severely deconditioned and continued to require high-flow nasal oxygen (FiO<sub>2</sub> 30–35%, 35 litres). Chest imaging was stable, demonstrating fibrosis but minimal progressive inflammation. The persistent detection of SARS-CoV-2 RNA and isolation of SARS-CoV-2 by culture (Box 2) from upper respiratory tract samples prevented participation in enhanced inpatient pulmonary rehabilitation beyond her single room, as per local infection prevention guidelines and hospital policy.<span><sup>3</sup></span> The policy, based on national guidelines,<span><sup>3</sup></span> dictated that for coronavirus disease 2019 (COVID-19) de-isolation, immunocompromised hosts need to be 21 days post-infection, asymptomatic, and without detectable SARS-CoV-2 RNA. In individuals with persistent RNA detection, a cycle threshold greater than 30 with either positive spike antibody, negative rapid antigen test (RAT) or culture is sufficient for de-isolation.</p><p>The patient received a further dose of tixagevimab–cilgavimab, regular intravenous immunoglobulin and ten further days of remdesivir. Repeat whole genome sequencing did not identify infection with anothe
{"title":"Prolonged SARS-CoV-2 shedding in a lung transplant recipient: time for flexibility in infection prevention?","authors":"Alyssa Pradhan,&nbsp;David Pham,&nbsp;Alexander Brennan,&nbsp;Jen Kok,&nbsp;Priya Garg","doi":"10.5694/mja2.52556","DOIUrl":"10.5694/mja2.52556","url":null,"abstract":"&lt;p&gt;A 39-year-old woman underwent bilateral sequential lung transplantation for fibrotic hypersensitivity pneumonitis in May 2022. Her immunosuppression treatment included prednisolone, tacrolimus and mycophenolate. She received one dose of Comirnaty (Pfizer) pre-transplant and tixagevimab–cilgavimab in June 2022.&lt;/p&gt;&lt;p&gt;Her first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed on 14 December 2022 and she was treated with molnupiravir for five days. On Day 11 of illness, she presented to hospital in respiratory distress with hypoxia (SpO2; 73% on room air). SARS-CoV-2 RNA was detected by polymerase chain reaction (PCR) with a cycle threshold of 21.8 (cobas SARS-CoV-2 and Influenza A/B, Roche). A chest computed tomography scan demonstrated extensive bilateral ground-glass opacification (Box 1). She required intensive care unit admission for high-flow nasal oxygen (FiO&lt;sub&gt;2&lt;/sub&gt; 60%, flow rate 50 litres) and received tocilizumab, ten days of remdesivir, increased prednisolone, and piperacillin–tazobactam. Three days of pulsed methylprednisolone was prescribed for possible transplant rejection. Despite clinical improvement, SARS-CoV-2 RNA remained detectable with a cycle threshold of 16.2 (VIASURE SARS-CoV-2, flu and RSV, Certest Biotec) and SARS-CoV-2 was isolated from a cell culture.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Whole genome sequencing identified Omicron BR.2 (variant of concern B.1.1.529) lineage, with molnupiravir-associated mutational signatures,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; (sequence available on GISAID [Global Initiative of Sharing All Influenza Data]; 26/12/22: hCoV-19/Australia/NSW_ICPMR_40135/2022 and 03/03/23: hCoV-19/Australia/NSW_ICPMR_43136/2023).&lt;/p&gt;&lt;p&gt;The patient was transferred to a high acuity respiratory ward after three weeks, but over the ensuing six weeks, became severely deconditioned and continued to require high-flow nasal oxygen (FiO&lt;sub&gt;2&lt;/sub&gt; 30–35%, 35 litres). Chest imaging was stable, demonstrating fibrosis but minimal progressive inflammation. The persistent detection of SARS-CoV-2 RNA and isolation of SARS-CoV-2 by culture (Box 2) from upper respiratory tract samples prevented participation in enhanced inpatient pulmonary rehabilitation beyond her single room, as per local infection prevention guidelines and hospital policy.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The policy, based on national guidelines,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; dictated that for coronavirus disease 2019 (COVID-19) de-isolation, immunocompromised hosts need to be 21 days post-infection, asymptomatic, and without detectable SARS-CoV-2 RNA. In individuals with persistent RNA detection, a cycle threshold greater than 30 with either positive spike antibody, negative rapid antigen test (RAT) or culture is sufficient for de-isolation.&lt;/p&gt;&lt;p&gt;The patient received a further dose of tixagevimab–cilgavimab, regular intravenous immunoglobulin and ten further days of remdesivir. Repeat whole genome sequencing did not identify infection with anothe","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 2","pages":"69-71"},"PeriodicalIF":6.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52556","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japanese encephalitis transmission in Australia: challenges and future perspectives 日本脑炎在澳大利亚的传播:挑战和未来展望。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-09 DOI: 10.5694/mja2.52550
Caroline K Dowsett, Francesca Frentiu, Gregor J Devine, Wenbiao Hu
<p>Japanese encephalitis is caused by the Japanese encephalitis virus (JEV). JEV is the main cause of viral encephalitis in Asia,<span><sup>1</sup></span> and is endemic in many countries on that continent and islands of the Pacific region. Although only a small percentage of cases are symptomatic, 20–30% are fatal and 30–50% develop significant neurological sequelae.<span><sup>2</sup></span> Australia has escaped relatively unscathed, with only a few cases detected in the late 1990s, mostly from international travellers, with local transmission limited to the Torres Strait and Cape York.<span><sup>2, 3</sup></span> The last detection of JEV in Cape York was from feral pigs and an isolate of mosquitoes in 2005. Sentinel animal surveillance in Australia was phased out in 2011 due to costs and labour-intensive maintenance, potential occupational health and safety issues, and concerns about the potential public health risk of using amplifying hosts (pigs), which may contribute to transmission when they become viremic.<span><sup>3</sup></span> Sentinel animal use was replaced by a general mosquito trap-based surveillance system.<span><sup>3</sup></span> The Box provides a timeline of JEV milestones in Australia from the 1990s to 2023, with details on animal and human cases, and corresponding changes in surveillance.</p><p>JEV emerged again in 2021 with a fatal case in the Tiwi Islands, and shortly after was detected on an unprecedented scale and geographical spread in 2022: cases in humans and piggeries were detected across four states in south-eastern Australia (New South Wales, Victoria, Queensland, South Australia). On 4 March 2022, the Australian Government declared the JEV outbreak a communicable disease incident of national significance.<span><sup>4</sup></span> Over the following months, a total of 46 cases (including 7 deaths) were identified in humans (as of 13 February 2023).<span><sup>5</sup></span> The end of the JEV emergency response was announced on 16 June 2023,<span><sup>6</sup></span> although concern remains regarding potential endemicity in Australian waterbird, pig and mosquito populations.</p><p>JEV is maintained in an enzootic cycle between wading waterbirds and <i>Culex</i> spp mosquitoes and, in some cases, pigs, with spillover to humans and horses.<span><sup>7</sup></span> Birds act as maintenance hosts and can harbour the virus without overt signs of disease. Humans and horses are dead-end hosts and may become infected through the bite of an infectious mosquito. However, dead-end hosts cannot produce virus levels high enough to infect feeding mosquitoes. In Asia, pigs commonly act as amplifying hosts, rapidly multiplying the virus to high levels that can be passed on to susceptible mosquito species, resulting in spillover to humans. There is no evidence of pigs acting as amplifying hosts during the 2021–2023 outbreak in Australia.</p><p>The dominant JEV vector in Australia and parts of the Western Pacific (such as Papua New
{"title":"Japanese encephalitis transmission in Australia: challenges and future perspectives","authors":"Caroline K Dowsett,&nbsp;Francesca Frentiu,&nbsp;Gregor J Devine,&nbsp;Wenbiao Hu","doi":"10.5694/mja2.52550","DOIUrl":"10.5694/mja2.52550","url":null,"abstract":"&lt;p&gt;Japanese encephalitis is caused by the Japanese encephalitis virus (JEV). JEV is the main cause of viral encephalitis in Asia,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; and is endemic in many countries on that continent and islands of the Pacific region. Although only a small percentage of cases are symptomatic, 20–30% are fatal and 30–50% develop significant neurological sequelae.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Australia has escaped relatively unscathed, with only a few cases detected in the late 1990s, mostly from international travellers, with local transmission limited to the Torres Strait and Cape York.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; The last detection of JEV in Cape York was from feral pigs and an isolate of mosquitoes in 2005. Sentinel animal surveillance in Australia was phased out in 2011 due to costs and labour-intensive maintenance, potential occupational health and safety issues, and concerns about the potential public health risk of using amplifying hosts (pigs), which may contribute to transmission when they become viremic.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Sentinel animal use was replaced by a general mosquito trap-based surveillance system.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The Box provides a timeline of JEV milestones in Australia from the 1990s to 2023, with details on animal and human cases, and corresponding changes in surveillance.&lt;/p&gt;&lt;p&gt;JEV emerged again in 2021 with a fatal case in the Tiwi Islands, and shortly after was detected on an unprecedented scale and geographical spread in 2022: cases in humans and piggeries were detected across four states in south-eastern Australia (New South Wales, Victoria, Queensland, South Australia). On 4 March 2022, the Australian Government declared the JEV outbreak a communicable disease incident of national significance.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Over the following months, a total of 46 cases (including 7 deaths) were identified in humans (as of 13 February 2023).&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The end of the JEV emergency response was announced on 16 June 2023,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; although concern remains regarding potential endemicity in Australian waterbird, pig and mosquito populations.&lt;/p&gt;&lt;p&gt;JEV is maintained in an enzootic cycle between wading waterbirds and &lt;i&gt;Culex&lt;/i&gt; spp mosquitoes and, in some cases, pigs, with spillover to humans and horses.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Birds act as maintenance hosts and can harbour the virus without overt signs of disease. Humans and horses are dead-end hosts and may become infected through the bite of an infectious mosquito. However, dead-end hosts cannot produce virus levels high enough to infect feeding mosquitoes. In Asia, pigs commonly act as amplifying hosts, rapidly multiplying the virus to high levels that can be passed on to susceptible mosquito species, resulting in spillover to humans. There is no evidence of pigs acting as amplifying hosts during the 2021–2023 outbreak in Australia.&lt;/p&gt;&lt;p&gt;The dominant JEV vector in Australia and parts of the Western Pacific (such as Papua New","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 2","pages":"58-62"},"PeriodicalIF":6.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52550","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke in young women: the need for targeted prevention and treatment strategies 年轻女性中风:需要有针对性的预防和治疗策略。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52516
Cheryl Carcel, Kylie Tastula, Amanda Henry
<p>Stroke is a devastating disease, leaving survivors with physical and cognitive impairments, and emotional and psychological instability. In 2021, the most current year available, the coronavirus disease 2019 (COVID-19) pandemic shifted the rankings of the <i>Global Burden of Disease Study</i>, bringing stroke down to the third leading cause of death worldwide,<span><sup>1</sup></span> and fourth leading cause of disability-adjusted life years.<span><sup>2</sup></span> In Australia, in 2022, cerebrovascular disease (mostly stroke) was the third leading cause of death in women compared with fifth in men.<span><sup>3</sup></span></p><p>Women have a lower age-adjusted incidence of stroke than men.<span><sup>4</sup></span> However, on age group breakdowns, authors of a recent meta-analysis of 16 studies (33 775 women and 36 018 men) found that sex difference in ischaemic stroke incidence was the greatest in adults younger than 35 years of age, with an estimated 44% more women than men.<span><sup>5</sup></span> These findings, showing that young women may be disproportionately at risk of ischaemic stroke, represent a significant shift from our current understanding, with important implications regarding causes and potential management of ischaemic strokes in young adults.</p><p>We acknowledge that the studies referenced herein use mostly sex data. However, in this perspective article, we use the term “women” in a binary manner to denote females.</p><p>There are key modifiable risk factors that are more strongly associated with stroke risk in women than in men. In the <i>UK Biobank Study</i> of 471 971 individuals (56% women),<span><sup>6</sup></span> in women, hypertension and obesity were associated with a 30% greater risk of stroke, and smoking and type 2 diabetes a 20–25% greater risk of stroke, compared with men.</p><p>In young women, non-atherosclerotic factors that increase the risk of stroke may be important. These include female-specific risk factors such as exogenous hormones and pregnancy-related exposures. Hormonal contraceptives are very effective, reliable and provide women with multiple health benefits. Combined oral contraceptives (COCs) containing oestrogen and progestogen carry an increased risk of arterial thrombosis, with a Cochrane systematic review noting a 1.7-fold increased risk of ischaemic stroke compared with non-users (relative risk [RR], 1.7; 95% confidence interval [CI], 1.5–1.9). The risk increased the higher the dose of oestrogen.<span><sup>7</sup></span> In a separate meta-analysis (six case–control studies), progestogen-only contraceptives were not associated with stroke when compared with individuals that had never used or formerly used this type of contraceptive.<span><sup>8</sup></span> Although overall COC-use ischaemic stroke risk is low for individuals, women with migraine who also use COCs have a further increased risk (RR, 7.02 [95% CI, 1.51–32.68]) while women experiencing a migraine with aura, COC use, and
中风是一种毁灭性的疾病,给幸存者留下身体和认知障碍,以及情绪和心理不稳定。在可获得的最新年份2021年,2019年冠状病毒病(COVID-19)大流行改变了《全球疾病负担研究》的排名,使中风降至全球第三大死亡原因1和第四大残疾调整生命年原因2在澳大利亚,2022年脑血管疾病(主要是中风)是妇女死亡的第三大原因,而在男子中排名第五。女性中风的年龄调整发生率低于男性然而,在年龄组细分方面,作者最近对16项研究(33775名女性和36018名男性)进行了荟萃分析,发现35岁以下的成年人缺血性中风发病率的性别差异最大,估计女性比男性多44%这些发现表明,年轻女性患缺血性卒中的风险可能不成比例,代表了我们目前认识的重大转变,对年轻人缺血性卒中的病因和潜在管理具有重要意义。我们承认本文引用的研究大多使用性别数据。然而,在这篇透视文章中,我们以二进制的方式使用术语“women”来表示女性。有一些关键的可改变的危险因素与女性中风风险的关系比男性更强。在英国生物银行对47971人(56%为女性)的研究中,与男性相比,高血压和肥胖与中风风险增加30%有关,吸烟和2型糖尿病与中风风险增加20-25%有关。在年轻女性中,非动脉粥样硬化因素可能是增加中风风险的重要因素。其中包括女性特有的风险因素,如外源性激素和与妊娠有关的暴露。激素避孕药非常有效、可靠,并为妇女提供多种健康益处。含有雌激素和孕激素的联合口服避孕药(COCs)会增加动脉血栓形成的风险,Cochrane系统评价指出,与不服用避孕药的人相比,缺血性卒中的风险增加1.7倍(相对风险[RR], 1.7;95%置信区间[CI], 1.5-1.9)。雌激素剂量越高,患病风险越高在一项单独的荟萃分析(六项病例对照研究)中,与从未使用或曾经使用过孕激素避孕药的个体相比,仅使用孕激素避孕药与中风无关尽管整体使用COC的个体缺血性卒中风险较低,但同时使用COC的偏头痛女性的风险进一步增加(RR, 7.02 [95% CI, 1.51-32.68]),而患有先兆偏头痛、使用COC和活跃吸烟者的风险增加了10倍(RR, 10 [95% CI, 1.4-73.7])。妊娠相关并发症,包括先兆子痫(1 / 30妊娠)和妊娠期糖尿病(1 / 7妊娠),会增加妊娠期和以后生活中中风的风险。怀孕期间,每10万例妊娠中有30例发生中风,子痫前期进一步增加出血性中风(RR,约10倍)和缺血性中风(RR, 40倍)的风险,继发于子痫前期内皮病变和妊娠期间雌激素相关高凝血症引起的高血压妊娠期糖尿病和妊娠期高血压会增加年轻女性中风的风险。最近一项关于GDM后心脑血管疾病风险的荟萃分析发现,卒中风险增加40% (95% CI, 1.29-1.51), 10年妊娠后糖尿病的心脑血管事件RR为1.46 (95% CI, 1.32-1.61)高血压妊娠后,对12项研究的荟萃分析发现,产后10年内卒中风险增加一倍以上(RR, 2.64, 95%;CI, 2.15 - -3.35)点虽然没有纳入心血管疾病风险计算,也没有在2023年澳大利亚心血管疾病风险评估和管理指南中作为正式的风险重新分类,但该指南确实指出,妊娠糖尿病和妊娠高血压疾病的妊娠并发症是重要的风险考虑因素这些指南建议在进行心血管风险评估时全面了解妊娠史,并强调对妊娠期糖尿病和/或高血压疾病的妇女进行随访预约的重要性。其他生殖代谢紊乱,如多囊卵巢综合征,也与中风风险增加有关,这可能是由于多囊卵巢综合征中胰岛素抵抗、肥胖、高血压、慢性炎症和氧化应激等传统和非传统心血管风险因素升高所致。现有的对中风的诊断和认识上的差异加剧了女性中风后的不良结果,她们更有可能在中风后生活质量下降。 15与男性相比,年轻女性在院前和急诊科被诊断为中风的可能性较小,这可能是由于全身无力、精神错乱或疲劳等非典型表现,17这些不太常被认为是中风症状。妇女往往是儿童和/或年迈父母的主要照顾者,她们可能不优先考虑自己的保健需要(如中风症状),而继续照顾他人。人们对这一点知之甚少,需要进一步研究。保健方面的偏见导致诊断延误,妇女的症状往往被错误地归因于非神经系统原因及时识别和诊断卒中是启动再灌注治疗的必要条件,这将大大改善功能预后。解决这些识别和诊断方面的差异需要多方面的解决方案。对于预防,高血压妊娠和GDM后的产后随访,以筛查、减少和控制中风危险因素,如慢性高血压和2型糖尿病,是关键适当使用COC,包括对高危妇女(如偏头痛妇女或吸烟妇女)考虑长效可逆避孕等替代方法也很重要。加强院前卒中识别至关重要。提高公众对妇女中风症状的认识可以确保及时的医疗干预。对护理人员进行有关性别特异性症状和早期发现的高级中风培训,可以促进诊断和治疗。年轻患者的5年卒中复发风险可高达12%青少年中风诊所可以针对特定性别的危险因素提供最佳的中风预防和预防复发。这些诊所提供诊断、治疗、持续管理、预防和康复的多学科团队,包括但不限于神经科医生、中风护士、神经外科医生、心脏病专家、产科医生、其他专家、营养学家和社会工作者。个性化教育和预防战略可以针对年轻妇女的独特风险因素,如重返工作活动、照料责任和避孕药具的使用,量身定制。提高妇女在临床试验中的参与度对于获得卒中干预措施有效性和安全性的有力证据至关重要。应侧重于设计包容性临床试验,以充分代表不同社会人口特征的妇女。监管机构和资助机构可以通过政策规定和作为资助要求的一部分来激励妇女参与。在临床试验中实施针对性别的分析(有效性和安全性)将为男女治疗效果的差异提供有价值的见解。总而言之,女性中风后的预后更差通过有针对性的干预措施、改善院前认知和增加临床试验的参与来应对这些挑战,对于缩小卒中结局方面的性别差距和确保公平的医疗保健至关重要。无相关披露。外部同行评审。
{"title":"Stroke in young women: the need for targeted prevention and treatment strategies","authors":"Cheryl Carcel,&nbsp;Kylie Tastula,&nbsp;Amanda Henry","doi":"10.5694/mja2.52516","DOIUrl":"10.5694/mja2.52516","url":null,"abstract":"&lt;p&gt;Stroke is a devastating disease, leaving survivors with physical and cognitive impairments, and emotional and psychological instability. In 2021, the most current year available, the coronavirus disease 2019 (COVID-19) pandemic shifted the rankings of the &lt;i&gt;Global Burden of Disease Study&lt;/i&gt;, bringing stroke down to the third leading cause of death worldwide,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; and fourth leading cause of disability-adjusted life years.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In Australia, in 2022, cerebrovascular disease (mostly stroke) was the third leading cause of death in women compared with fifth in men.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Women have a lower age-adjusted incidence of stroke than men.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; However, on age group breakdowns, authors of a recent meta-analysis of 16 studies (33 775 women and 36 018 men) found that sex difference in ischaemic stroke incidence was the greatest in adults younger than 35 years of age, with an estimated 44% more women than men.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; These findings, showing that young women may be disproportionately at risk of ischaemic stroke, represent a significant shift from our current understanding, with important implications regarding causes and potential management of ischaemic strokes in young adults.&lt;/p&gt;&lt;p&gt;We acknowledge that the studies referenced herein use mostly sex data. However, in this perspective article, we use the term “women” in a binary manner to denote females.&lt;/p&gt;&lt;p&gt;There are key modifiable risk factors that are more strongly associated with stroke risk in women than in men. In the &lt;i&gt;UK Biobank Study&lt;/i&gt; of 471 971 individuals (56% women),&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; in women, hypertension and obesity were associated with a 30% greater risk of stroke, and smoking and type 2 diabetes a 20–25% greater risk of stroke, compared with men.&lt;/p&gt;&lt;p&gt;In young women, non-atherosclerotic factors that increase the risk of stroke may be important. These include female-specific risk factors such as exogenous hormones and pregnancy-related exposures. Hormonal contraceptives are very effective, reliable and provide women with multiple health benefits. Combined oral contraceptives (COCs) containing oestrogen and progestogen carry an increased risk of arterial thrombosis, with a Cochrane systematic review noting a 1.7-fold increased risk of ischaemic stroke compared with non-users (relative risk [RR], 1.7; 95% confidence interval [CI], 1.5–1.9). The risk increased the higher the dose of oestrogen.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; In a separate meta-analysis (six case–control studies), progestogen-only contraceptives were not associated with stroke when compared with individuals that had never used or formerly used this type of contraceptive.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Although overall COC-use ischaemic stroke risk is low for individuals, women with migraine who also use COCs have a further increased risk (RR, 7.02 [95% CI, 1.51–32.68]) while women experiencing a migraine with aura, COC use, and ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"571-572"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health service access and quality of care provided by the Western NSW Local Health District Virtual Rural Generalist Service: a retrospective analysis of linked administrative data 新南威尔士州西部地方卫生区虚拟农村通才服务提供的保健服务的可及性和保健质量:对相关行政数据的回顾性分析。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52528
Georgina M Luscombe, Andrew Wilson, Amanda J Ampt, Amy Von Huben, Kirsten Howard, Clare Coleman, Georgia Wingfield, Shannon Nott
<div> <section> <h3> Objective</h3> <p>To evaluate the quantity and quality of medical care provided by the Western NSW Local Health District Virtual Rural Generalist Service (VRGS).</p> </section> <section> <h3> Design</h3> <p>Retrospective cohort study; analysis of emergency department and administrative hospital data.</p> </section> <section> <h3> Setting</h3> <p>Twenty-nine rural or remote hospitals in the Western NSW Local Health District at which the VRGS was providing medical care in the emergency department (ED) and/or inpatient setting. The VRGS was providing predominantly virtual medical support when local doctors needed relief or were unavailable, typically for lower acuity ED presentations and scheduled inpatient ward rounds.</p> </section> <section> <h3> Patients</h3> <p>All patients who presented or were admitted to a Western NSW Local Health District hospital serviced by the VRGS between 1 July 2021 and 30 June 2022.</p> </section> <section> <h3> Main outcome measures</h3> <p>Treatment completions, transfers, ED departure within 4 hours, length of stay, and hospital mortality.</p> </section> <section> <h3> Results</h3> <p>During 2021–22, 34% of ED presentations (13 660/39 701) and 40% of admissions (2531/6328) involved VRGS care. For ED presentations, after adjusting for socio-demographic and clinical factors, patients attended by VRGS doctors had higher odds of not waiting (adjusted odds ratio [aOR], 3.69; 95% CI, 2.79–4.89), lower odds of transfer to another hospital (aOR, 0.66; 95% CI, 0.60–0.72) and slightly lower odds of ED departure within 4 hours (aOR, 0.92; 95% CI, 0.86–0.98) when compared with patients not attended by VRGS doctors (ie, those provided usual care). For admissions, after adjusting for socio-demographic and clinical factors, inpatients attended exclusively by VRGS doctors had higher odds of discharging at their own risk (3.33; 95% CI, 1.98–5.61) and lower odds of being a long stay outlier (aOR, 0.51; 95% CI, 0.35–0.74) when compared with inpatients not attended by VRGS doctors. The odds of inpatient mortality were equivalent when comparing VRGS and non-VRGS care (aOR, 0.78; 95% CI, 0.48–1.28) and when comparing combined (VRGS and non-VRGS) and non-VRGS care (aOR 1.21; 95% CI, 0.91–1.61).</p> </section> <section> <h3> Conclusions</h3>
目的:评价新南威尔士州西部地方卫生区虚拟农村通才服务(VRGS)提供的医疗服务的数量和质量。设计:回顾性队列研究;急诊科及行政医院资料分析。环境:新南威尔士州西部地方卫生区的29家农村或偏远医院,VRGS在这些医院的急诊科和/或住院部提供医疗服务。VRGS主要是在当地医生需要缓解或没空的情况下提供虚拟医疗支持,通常是针对低视力急诊科的介绍和安排的住院病房查房。患者:在2021年7月1日至2022年6月30日期间在由VRGS服务的新南威尔士州西部地方卫生区医院就诊或住院的所有患者。主要结局指标:治疗完成、转院、4小时内离开急诊室、住院时间和住院死亡率。结果:在2021- 2022年期间,34%的ED患者(13 660/39 701)和40%的入院患者(2531/6328)涉及VRGS护理。对于ED的表现,在调整了社会人口统计学和临床因素后,由VRGS医生就诊的患者不等待的几率更高(调整后的优势比[aOR], 3.69;95% CI, 2.79-4.89),转院几率较低(aOR, 0.66;95% CI, 0.60-0.72), 4小时内ED离开的几率略低(aOR, 0.92;95% CI, 0.86-0.98),与未接受VRGS医生治疗的患者(即提供常规护理的患者)相比。入院方面,在调整了社会人口统计学和临床因素后,由VRGS医生专治的住院患者自行出院的几率更高(3.33;95% CI, 1.98-5.61)和较低的长期异常率(aOR, 0.51;95% CI, 0.35-0.74),与没有VRGS医生就诊的住院患者相比。当比较VRGS和非VRGS护理时,住院患者死亡率的几率相等(aOR, 0.78;95% CI, 0.48-1.28),当比较联合(VRGS和非VRGS)和非VRGS护理时(aOR 1.21;95% ci, 0.91-1.61)。结论:在当前农村医疗人员短缺的环境下,VRGS在常规收集的医疗质量指标上取得了相似的结果。这显然是补充和加强在当地医疗服务有限或没有医疗服务的农村和偏远社区提供医疗服务的一种选择。
{"title":"Health service access and quality of care provided by the Western NSW Local Health District Virtual Rural Generalist Service: a retrospective analysis of linked administrative data","authors":"Georgina M Luscombe,&nbsp;Andrew Wilson,&nbsp;Amanda J Ampt,&nbsp;Amy Von Huben,&nbsp;Kirsten Howard,&nbsp;Clare Coleman,&nbsp;Georgia Wingfield,&nbsp;Shannon Nott","doi":"10.5694/mja2.52528","DOIUrl":"10.5694/mja2.52528","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the quantity and quality of medical care provided by the Western NSW Local Health District Virtual Rural Generalist Service (VRGS).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective cohort study; analysis of emergency department and administrative hospital data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Twenty-nine rural or remote hospitals in the Western NSW Local Health District at which the VRGS was providing medical care in the emergency department (ED) and/or inpatient setting. The VRGS was providing predominantly virtual medical support when local doctors needed relief or were unavailable, typically for lower acuity ED presentations and scheduled inpatient ward rounds.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Patients&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;All patients who presented or were admitted to a Western NSW Local Health District hospital serviced by the VRGS between 1 July 2021 and 30 June 2022.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcome measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Treatment completions, transfers, ED departure within 4 hours, length of stay, and hospital mortality.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;During 2021–22, 34% of ED presentations (13 660/39 701) and 40% of admissions (2531/6328) involved VRGS care. For ED presentations, after adjusting for socio-demographic and clinical factors, patients attended by VRGS doctors had higher odds of not waiting (adjusted odds ratio [aOR], 3.69; 95% CI, 2.79–4.89), lower odds of transfer to another hospital (aOR, 0.66; 95% CI, 0.60–0.72) and slightly lower odds of ED departure within 4 hours (aOR, 0.92; 95% CI, 0.86–0.98) when compared with patients not attended by VRGS doctors (ie, those provided usual care). For admissions, after adjusting for socio-demographic and clinical factors, inpatients attended exclusively by VRGS doctors had higher odds of discharging at their own risk (3.33; 95% CI, 1.98–5.61) and lower odds of being a long stay outlier (aOR, 0.51; 95% CI, 0.35–0.74) when compared with inpatients not attended by VRGS doctors. The odds of inpatient mortality were equivalent when comparing VRGS and non-VRGS care (aOR, 0.78; 95% CI, 0.48–1.28) and when comparing combined (VRGS and non-VRGS) and non-VRGS care (aOR 1.21; 95% CI, 0.91–1.61).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S11","pages":"S8-S15"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52528","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An economic evaluation of the Virtual Rural Generalist Service versus usual care in Western NSW Local Health District 新南威尔士州西部地方卫生区的虚拟农村通才服务与常规护理的经济评估。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52530
Amy Von Huben, Anna E Thompson, Andrew Wilson, Georgina M Luscombe, Amelia Haigh, Kirsten Howard, Emily Saurman, Tim Shaw, Georgia Wingfield, Amanda J Ampt, Shannon Nott
<div> <section> <h3> Objective</h3> <p>Evaluate the cost-effectiveness of the Virtual Rural Generalist Service (VRGS) model of care.</p> </section> <section> <h3> Design</h3> <p>A cost–consequence analysis of the VRGS model of care compared with usual care (treatment by local or locum [non-VRGS] doctors) from the perspective of the health care funder in 2022 prices.</p> </section> <section> <h3> Setting</h3> <p>Twenty-nine rural and remote hospitals in the Western NSW Local Health District where the VRGS has been in operation (VRGS sites).</p> </section> <section> <h3> Patients</h3> <p>Patients of any age who presented to an emergency department (ED) or were admitted to hospital at VRGS sites over the pre-VRGS period (1 February 2019 to 31 January 2020) or the post-VRGS period (1 July 2021 to 30 June 2022).</p> </section> <section> <h3> Intervention</h3> <p>The VRGS model of care, which provides 24-hour 7-days-a-week rural generalist doctors, both virtually and in person, to small rural and remote hospitals, predominantly for lower acuity ED presentations, daily ward rounds for inpatients admitted by a VRGS medical officer, and ad hoc inpatient medical reviews when local doctors need support or are unavailable.</p> </section> <section> <h3> Main outcomes measures</h3> <p>Incremental cost per incremental quality-of-care outcome, maintenance of health service activity levels, workforce sustainability (measured by changes in locum shifts), and service acceptability (as determined by thematic analysis of interviews).</p> </section> <section> <h3> Results</h3> <p>The cost per standard unit of health care (national weighted activity unit) was lower for the VRGS ($1047) than for usual care ($1753). VRGS doctors dealt with ED presentations of similar complexity to non-VRGS doctors, and admissions of significantly lower (40%) complexity. Health service activity remained stable from the pre-VRGS period to the post-VRGS period, only declining by 4% in the post-VRGS period, which was during the coronavirus disease 2019 pandemic. Locum shifts decreased from 1456 days in the pre-VRGS period to 609 days in the post-VRGS period, improving the sustainability of the workforce. Local doctors and managers found the VRGS to be acceptable, but thought it could be enhanc
目的:评价虚拟农村全科服务(VRGS)模式的成本效益。设计:从医疗资助者的角度对2022年价格下VRGS模式与常规护理(由当地或当地[非VRGS]医生治疗)的成本-后果进行分析。环境:在开展VRGS的新南威尔士州西部地方卫生区的29家农村和偏远医院(VRGS站点)。患者:在VRGS前(2019年2月1日至2020年1月31日)或VRGS后(2021年7月1日至2022年6月30日)期间在VRGS站点就诊或住院的任何年龄的患者。干预措施:VRGS的护理模式,向小型农村和偏远医院提供每周7天24小时的农村全科医生,包括虚拟的和亲自的,主要用于低度急诊科的诊察,VRGS医务官员每天对住院病人进行查房,并在当地医生需要支持或无法获得支持时对住院病人进行临时医疗检查。主要结果衡量指标:每增加的护理质量结果的增量成本、卫生服务活动水平的维持、劳动力的可持续性(通过临时轮班的变化来衡量)和服务的可接受性(通过访谈的专题分析来确定)。结果:VRGS的每标准单位卫生保健(国家加权活动单位)成本(1047美元)低于常规护理(1753美元)。VRGS医生处理ED表现的复杂性与非VRGS医生相似,入院复杂性显著降低(40%)。从vrgs之前到vrgs之后,卫生服务活动保持稳定,仅在vrgs之后(即2019年冠状病毒大流行期间)下降了4%。本地轮班从vrgs前的1456天减少到vrgs后的609天,提高了劳动力的可持续性。当地医生和管理人员认为VRGS是可以接受的,但认为可以通过对护理和技术人员的额外投资来提高VRGS。结论:我们对VRGS的经济评估表明,与常规护理相比,VRGS提供了更低的成本护理和同等质量的护理结果,并支持当地临床工作人员在大流行期间保持活动水平。通过对数据采集以及护理和技术人员的额外投资来支持这项服务,VRGS有望成为一项灵活的服务,有助于农村和偏远社区持续获得高质量的医疗服务。
{"title":"An economic evaluation of the Virtual Rural Generalist Service versus usual care in Western NSW Local Health District","authors":"Amy Von Huben,&nbsp;Anna E Thompson,&nbsp;Andrew Wilson,&nbsp;Georgina M Luscombe,&nbsp;Amelia Haigh,&nbsp;Kirsten Howard,&nbsp;Emily Saurman,&nbsp;Tim Shaw,&nbsp;Georgia Wingfield,&nbsp;Amanda J Ampt,&nbsp;Shannon Nott","doi":"10.5694/mja2.52530","DOIUrl":"10.5694/mja2.52530","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Evaluate the cost-effectiveness of the Virtual Rural Generalist Service (VRGS) model of care.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A cost–consequence analysis of the VRGS model of care compared with usual care (treatment by local or locum [non-VRGS] doctors) from the perspective of the health care funder in 2022 prices.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Twenty-nine rural and remote hospitals in the Western NSW Local Health District where the VRGS has been in operation (VRGS sites).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Patients&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Patients of any age who presented to an emergency department (ED) or were admitted to hospital at VRGS sites over the pre-VRGS period (1 February 2019 to 31 January 2020) or the post-VRGS period (1 July 2021 to 30 June 2022).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Intervention&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The VRGS model of care, which provides 24-hour 7-days-a-week rural generalist doctors, both virtually and in person, to small rural and remote hospitals, predominantly for lower acuity ED presentations, daily ward rounds for inpatients admitted by a VRGS medical officer, and ad hoc inpatient medical reviews when local doctors need support or are unavailable.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcomes measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Incremental cost per incremental quality-of-care outcome, maintenance of health service activity levels, workforce sustainability (measured by changes in locum shifts), and service acceptability (as determined by thematic analysis of interviews).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The cost per standard unit of health care (national weighted activity unit) was lower for the VRGS ($1047) than for usual care ($1753). VRGS doctors dealt with ED presentations of similar complexity to non-VRGS doctors, and admissions of significantly lower (40%) complexity. Health service activity remained stable from the pre-VRGS period to the post-VRGS period, only declining by 4% in the post-VRGS period, which was during the coronavirus disease 2019 pandemic. Locum shifts decreased from 1456 days in the pre-VRGS period to 609 days in the post-VRGS period, improving the sustainability of the workforce. Local doctors and managers found the VRGS to be acceptable, but thought it could be enhanc","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S11","pages":"S28-S36"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52530","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient and carer experiences of hospital-based hybrid virtual medical care: a qualitative study 基于医院的混合虚拟医疗的患者和护理者体验:一项定性研究。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52520
Anna E Thompson, Tim Shaw, Shannon Nott, Andrew Wilson, Emily Saurman

Objectives

To understand patients’ and carers’ experiences of virtual medical care delivered into rural and remote hospitals.

Study design

Qualitative study using semi-structured interviews.

Setting, participants

Interviews were conducted between 7 June 2022 and 21 February 2023. Participants were people who had received a virtual medical service from the Virtual Rural Generalist Service (VRGS), and their carers, in rural and remote hospitals within the Western NSW Local Health District.

Main outcome measures

Acceptability of, access to, quality of and appropriateness of care provided by the VRGS.

Results

We interviewed 43 patients and carers about their experiences of VRGS services received in an emergency department or inpatient setting. About half of our participants thought that virtual medical care (supported by in-person nursing staff) was highly acceptable and equivalent to in-person care. For the remaining participants, virtual care was seen as being an acceptable alternative if in-person care was not available. Patients reported that the model met their immediate needs, even if the virtual delivery mode was not their preference. VRGS doctors were generally seen as skilled and personable, and acceptability of virtual care increased with more experience of it. A key perceived benefit of virtual care was increased access to medical care without the need to travel long distances. Hospital-based virtual care was not considered less appropriate for older adults or children.

Conclusions

Virtual care in a rural hospital setting, such as that delivered by the VRGS, is broadly acceptable to patients and carers. While most would prefer to have a doctor physically present, patients and carers are accepting of the need for virtual care to supplement in-person care in rural and remote areas. Patients and carers who experience hospital-based virtual care perceive that it can provide good quality medical care and meet many of their needs.

目的:了解农村和偏远地区医院虚拟医疗服务的患者和护理人员体验。研究设计:采用半结构化访谈的定性研究。环境、参与者:访谈于2022年6月7日至2023年2月21日进行。参与者是在新南威尔士州西部地方卫生区内的农村和偏远医院接受过虚拟农村通才服务(VRGS)的虚拟医疗服务的人及其护理人员。主要结果测量:VRGS提供的护理的可接受性、可及性、质量和适当性。结果:我们采访了43名患者和护理人员,了解他们在急诊科或住院环境中接受VRGS服务的经历。大约一半的参与者认为虚拟医疗(由现场护理人员支持)是高度可接受的,相当于现场护理。对于其余的参与者,如果没有面对面的护理,虚拟护理被视为一种可接受的替代方案。患者报告说,该模型满足了他们的直接需求,即使虚拟交付模式不是他们的偏好。VRGS医生通常被认为是熟练和风度翩翩的,虚拟护理的可接受性随着经验的增加而增加。人们认为虚拟医疗的一个主要好处是增加了获得医疗服务的机会,而无需长途跋涉。以医院为基础的虚拟护理并不被认为不适合老年人或儿童。结论:农村医院环境中的虚拟护理,如VRGS提供的虚拟护理,被患者和护理人员广泛接受。虽然大多数人更希望有医生在场,但在农村和偏远地区,患者和护理人员接受了虚拟护理的需要,以补充面对面的护理。体验基于医院的虚拟医疗的患者和护理人员认为,它可以提供高质量的医疗服务,并满足他们的许多需求。
{"title":"Patient and carer experiences of hospital-based hybrid virtual medical care: a qualitative study","authors":"Anna E Thompson,&nbsp;Tim Shaw,&nbsp;Shannon Nott,&nbsp;Andrew Wilson,&nbsp;Emily Saurman","doi":"10.5694/mja2.52520","DOIUrl":"10.5694/mja2.52520","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To understand patients’ and carers’ experiences of virtual medical care delivered into rural and remote hospitals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study design</h3>\u0000 \u0000 <p>Qualitative study using semi-structured interviews.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting, participants</h3>\u0000 \u0000 <p>Interviews were conducted between 7 June 2022 and 21 February 2023. Participants were people who had received a virtual medical service from the Virtual Rural Generalist Service (VRGS), and their carers, in rural and remote hospitals within the Western NSW Local Health District.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main outcome measures</h3>\u0000 \u0000 <p>Acceptability of, access to, quality of and appropriateness of care provided by the VRGS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We interviewed 43 patients and carers about their experiences of VRGS services received in an emergency department or inpatient setting. About half of our participants thought that virtual medical care (supported by in-person nursing staff) was highly acceptable and equivalent to in-person care. For the remaining participants, virtual care was seen as being an acceptable alternative if in-person care was not available. Patients reported that the model met their immediate needs, even if the virtual delivery mode was not their preference. VRGS doctors were generally seen as skilled and personable, and acceptability of virtual care increased with more experience of it. A key perceived benefit of virtual care was increased access to medical care without the need to travel long distances. Hospital-based virtual care was not considered less appropriate for older adults or children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Virtual care in a rural hospital setting, such as that delivered by the VRGS, is broadly acceptable to patients and carers. While most would prefer to have a doctor physically present, patients and carers are accepting of the need for virtual care to supplement in-person care in rural and remote areas. Patients and carers who experience hospital-based virtual care perceive that it can provide good quality medical care and meet many of their needs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S11","pages":"S22-S27"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52520","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Curating an evidence base for health research and policy making: more crucial than ever 管理卫生研究和政策制定的证据基础:比以往任何时候都更加重要。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52536
Virginia Barbour
<p>The end of the year is a good time to reflect on why a journal like the <i>MJA</i> does what it does, who supports the Journal's work, and the headwinds that journals are navigating.</p><p>The <i>MJA</i> publishes high quality research and commentary that aims to inform health policy and influence medical practice in Australia. Our process is largely one of curation of what is submitted to us, combined with commissioning on issues we identify as important. We prioritise for publication articles that report on or discuss conditions with a high burden of disease, that are likely to have an effect on policy or practice, support Aboriginal and Torres Strait Islander health and wellbeing, and articles that report on uniquely Australian topics.</p><p>Articles go through a rigorous process that includes editorial assessment, peer review, author revision in response to peer review, and, after acceptance, expert structural editing. We hope that this process — essentially a collaboration between authors, editors and reviewers — will ensure that, by the time an article is published, it is the best representation of the authors’ work. In the 12 months to 31 October 2024, the <i>MJA</i> received 1598 articles, of which 196 were accepted; we publish around 10–12 in each issue. Each issue is a curated mix of content; some, such as the theme issues on surgery (https://www.mja.com.au/journal/2024/220/5), general practice (https://www.mja.com.au/journal/2024/220/9), women's health (https://www.mja.com.au/journal/2024/221/7), infectious diseases (https://www.mja.com.au/journal/2024/221/4), child and adolescent health (https://www.mja.com.au/journal/2024/221/10), and the special issue on Indigenous health (https://www.mja.com.au/journal/2024/221/1), have a specific focus.</p><p>This end of year issue has no specific theme; its diversity, however, collectively reflects the Journal's priorities. We hope these articles will interest you as readers and support you in your clinical practice or research as much as we were fascinated by them as editors. The research articles include an analysis of the cost of treating hypertension (https://doi.org/10.5694/mja2.52522), participation in the national bowel screening program by people with severe mental illness (https://doi.org/10.5694/mja2.52521), an analysis of out-of-hospital cardiac arrests (https://doi.org/10.5694/mja2.52532), and an analysis of the Northern Territory health workforce (https://doi.org/10.5694/mja2.52507). Perspectives include the need for targeted prevention and treatment of stroke in young women (https://doi.org/10.5694/mja2.52516), and a review of the evidence of persistently replicating SARS-CoV-2 as a driver of long COVID (https://doi.org/10.5694/mja2.52517). We are proud to also publish in this section a thoughtful article, “Decolonisation, Indigenous health research, and Indigenous authorship: sharing our teams’ principles and practices” (https://doi.org/10.5694/mja2.52509), by a collective of Ab
年底是一个很好的时间来反思为什么像MJA这样的期刊要做它所做的事情,谁支持期刊的工作,以及期刊正在导航的逆风。MJA出版高质量的研究和评论,旨在为澳大利亚的卫生政策提供信息并影响医疗实践。我们的流程主要是对提交给我们的内容进行管理,并结合我们认为重要的问题进行委托。我们优先出版报道或讨论可能对政策或实践产生影响、支持土著和托雷斯海峡岛民健康和福祉的高疾病负担条件的文章,以及报道澳大利亚独特主题的文章。文章要经过一个严格的过程,包括编辑评估、同行评议、作者根据同行评议进行修改,并在接受后进行专家结构编辑。我们希望这一过程——本质上是作者、编辑和审稿人之间的合作——将确保在一篇文章发表时,它是作者工作的最佳代表。在截至2024年10月31日的12个月内,MJA收到了1598篇文章,其中196篇被接受;我们每期大约发表10-12篇文章。每期都是精心策划的内容组合;一些,比如主题问题手术(https://www.mja.com.au/journal/2024/220/5),惯例(https://www.mja.com.au/journal/2024/220/9),女性健康(https://www.mja.com.au/journal/2024/221/7),传染病(https://www.mja.com.au/journal/2024/221/4),儿童和青少年卫生(https://www.mja.com.au/journal/2024/221/10),和原住民健康特刊(https://www.mja.com.au/journal/2024/221/1),有一个特定的焦点。这期年终特刊没有具体的主题;然而,它的多样性总体上反映了《华尔街日报》的优先事项。我们希望这些文章能引起读者的兴趣,并在您的临床实践或研究中支持您,就像我们作为编辑被它们所吸引一样。研究文章包括对高血压治疗费用的分析(https://doi.org/10.5694/mja2.52522)、严重精神疾病患者参加全国肠道筛查方案(https://doi.org/10.5694/mja2.52521)、院外心脏骤停的分析(https://doi.org/10.5694/mja2.52532)和对北领地卫生人力的分析(https://doi.org/10.5694/mja2.52507)。观点包括需要有针对性地预防和治疗年轻女性中风(https://doi.org/10.5694/mja2.52516),以及对持续复制SARS-CoV-2作为长COVID驱动因素的证据的审查(https://doi.org/10.5694/mja2.52517)。我们还自豪地在本节发表一篇深思熟虑的文章,“非殖民化、土著健康研究和土著作者身份:分享我们团队的原则和做法” (https://doi.org/10.5694/mja2.52509),作者是一群土著和非土著研究人员,他们在两个土著领导的研究小组中共同工作。在我们在MJA做出决定的过程中,我们每天都得到许多审稿人的支持,他们花时间和专业知识帮助我们提供我们认为必不可少的服务:高质量的循证研究和评论,以支持医疗保健决策。在过去的12个月里,他们总共提交了855篇评论。我们在下面列出了过去12个月里为我们做过评审的评审人员名单,我们对他们为支持MJA所做的一切表示感谢。我们也非常感谢我们的编辑咨询小组成员,他们不断提供专家建议。今年,我们特别感谢我们与Lowitja研究所(https://www.mja.com.au/journal/2024/221/1)联合出版的关于土著健康的7月特刊的客座编辑。他们策划这期特刊的工作是我们非常自豪地支持的,这是MJA在土著和托雷斯海峡岛民领导的健康研究中不断致力于卓越和领导的一部分。到2024年,100多个国家(约占世界人口的一半)将有机会在地区、国家或地方选举中投票。也许,科学和医学的证据基础比以往任何时候都更受投票的影响,但并不清楚它在每一个案例中都是获胜的一方。在回顾我们所做的事情时,像MJA这样的同行评议期刊的作用在未来几年将更加重要,它将帮助我们浏览现有的大量医学信息。我们非常感谢所有支持我们在MJA工作的人,以及那些自己从事循证卫生研究和政策制定的人。现在,这项工作比以往任何时候都更加重要,可以支持一个正常运转和循证社会。MJA编辑咨询小组成员是杰出的临床医生和学者,他们是MJA的宝贵思想来源 年底是一个很好的时间来反思为什么像MJA这样的期刊要做它所做的事情,谁支持期刊的工作,以及期刊正在导航的逆风。MJA出版高质量的研究和评论,旨在为澳大利亚的卫生政策提供信息并影响医疗实践。我们的流程主要是对提交给我们的内容进行管理,并结合我们认为重要的问题进行委托。我们优先出版报道或讨论可能对政策或实践产生影响、支持土著和托雷斯海峡岛民健康和福祉的高疾病负担条件的文章,以及报道澳大利亚独特主题的文章。文章要经过一个严格的过程,包括编辑评估、同行评议、作者根据同行评议进行修改,并在接受后进行专家结构编辑。我们希望这一过程——本质上是作者、编辑和审稿人之间的合作——将确保在一篇文章发表时,它是作者工作的最佳代表。在截至2024年10月31日的12个月内,MJA收到了1598篇文章,其中196篇被接受;我们每期大约发表10-12篇文章。每期都是精心策划的内容组合;一些,比如主题问题手术(https://www.mja.com.au/journal/2024/220/5),惯例(https://www.mja.com.au/journal/2024/220/9),女性健康(https://www.mja.com.au/journal/2024/221/7),传染病(https://www.mja.com.au/journal/2024/221/4),儿童和青少年卫生(https://www.mja.com.au/journal/2024/221/10),和原住民健康特刊(https://www.mja.com.au/journal/2024/221/1),有一个特定的焦点。这期年终特刊没有具体的主题;然而,它的多样性总体上反映了《华尔街日报》的优先事项。我们希望这些文章能引起读者的兴趣,并在您的临床实践或研究中支持您,就像我们作为编辑被它们所吸引一样。研究文章包括对高血压治疗费用的分析(https://doi.org/10.5694/mja2.52522)、严重精神疾病患者参加全国肠道筛查方案(https://doi.org/10.5694/mja2.52521)、院外心脏骤停的分析(https://doi.org/10.5694/mja2.52532)和对北领地卫生人力的分析(https://doi.org/10.5694/mja2.52507)。观点包括需要有针对性地预防和治疗年轻女性中风(https://doi.org/10.5694/mja2.52516),以及对持续复制SARS-CoV-2作为长COVID驱动因素的证据的审查(https://doi.org/10.5694/mja2.52517)。我们还自豪地在本节发表一篇深思熟虑的文章,“非殖民化、土著健康
{"title":"Curating an evidence base for health research and policy making: more crucial than ever","authors":"Virginia Barbour","doi":"10.5694/mja2.52536","DOIUrl":"10.5694/mja2.52536","url":null,"abstract":"&lt;p&gt;The end of the year is a good time to reflect on why a journal like the &lt;i&gt;MJA&lt;/i&gt; does what it does, who supports the Journal's work, and the headwinds that journals are navigating.&lt;/p&gt;&lt;p&gt;The &lt;i&gt;MJA&lt;/i&gt; publishes high quality research and commentary that aims to inform health policy and influence medical practice in Australia. Our process is largely one of curation of what is submitted to us, combined with commissioning on issues we identify as important. We prioritise for publication articles that report on or discuss conditions with a high burden of disease, that are likely to have an effect on policy or practice, support Aboriginal and Torres Strait Islander health and wellbeing, and articles that report on uniquely Australian topics.&lt;/p&gt;&lt;p&gt;Articles go through a rigorous process that includes editorial assessment, peer review, author revision in response to peer review, and, after acceptance, expert structural editing. We hope that this process — essentially a collaboration between authors, editors and reviewers — will ensure that, by the time an article is published, it is the best representation of the authors’ work. In the 12 months to 31 October 2024, the &lt;i&gt;MJA&lt;/i&gt; received 1598 articles, of which 196 were accepted; we publish around 10–12 in each issue. Each issue is a curated mix of content; some, such as the theme issues on surgery (https://www.mja.com.au/journal/2024/220/5), general practice (https://www.mja.com.au/journal/2024/220/9), women's health (https://www.mja.com.au/journal/2024/221/7), infectious diseases (https://www.mja.com.au/journal/2024/221/4), child and adolescent health (https://www.mja.com.au/journal/2024/221/10), and the special issue on Indigenous health (https://www.mja.com.au/journal/2024/221/1), have a specific focus.&lt;/p&gt;&lt;p&gt;This end of year issue has no specific theme; its diversity, however, collectively reflects the Journal's priorities. We hope these articles will interest you as readers and support you in your clinical practice or research as much as we were fascinated by them as editors. The research articles include an analysis of the cost of treating hypertension (https://doi.org/10.5694/mja2.52522), participation in the national bowel screening program by people with severe mental illness (https://doi.org/10.5694/mja2.52521), an analysis of out-of-hospital cardiac arrests (https://doi.org/10.5694/mja2.52532), and an analysis of the Northern Territory health workforce (https://doi.org/10.5694/mja2.52507). Perspectives include the need for targeted prevention and treatment of stroke in young women (https://doi.org/10.5694/mja2.52516), and a review of the evidence of persistently replicating SARS-CoV-2 as a driver of long COVID (https://doi.org/10.5694/mja2.52517). We are proud to also publish in this section a thoughtful article, “Decolonisation, Indigenous health research, and Indigenous authorship: sharing our teams’ principles and practices” (https://doi.org/10.5694/mja2.52509), by a collective of Ab","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"567-570"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52536","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinician experiences of a hybrid virtual medical service supporting rural and remote hospitals: a qualitative study 支持农村和偏远医院的混合虚拟医疗服务的临床经验:一项定性研究。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-08 DOI: 10.5694/mja2.52525
Anna E Thompson, Emily Saurman, Shannon Nott, Andrew Wilson, Tim Shaw

Objectives

To explore the experiences of clinicians delivering, facilitating, and potentially affected by a hybrid virtual medical model servicing rural and remote hospitals in western New South Wales.

Design, setting, participants

Qualitative study using semi-structured focus groups and individual interviews, conducted between 7 April 2022 and 16 March 2023, with rural generalist doctors delivering the Virtual Rural Generalist Service (VRGS) within the Western NSW Local Health District, local site staff, and local general practitioner visiting medical officers (GP VMOs).

Main outcome measures

Key themes in clinician experience of the model and recommendations for improved experience, based on qualitative content analysis.

Results

We interviewed 12 VRGS doctors, 25 site nursing staff and nine GP VMOs. Clinicians were overwhelmingly positive about the VRGS, seeing it as providing good quality care and being an innovative and translatable solution to rural workforce challenges. In-person site visits by VRGS doctors were highly valued, especially by local site staff, for team building, skill building and increasing VRGS doctors’ understanding of the local context. The VRGS model relies on nursing availability and skill, and creates additional workload for nurses. Nurses in isolated sites valued the clinical support provided by the VRGS. Overall, most GP VMOs valued the fatigue relief offered by the VRGS; however, some viewed the VRGS as diminishing local doctors’ autonomy and the viability of their positions.

Conclusions

The hybrid VRGS model is widely accepted by clinicians as providing good quality care for patients and high job satisfaction for providers. The service supports the local health workforce and makes rural medical positions more attractive and sustainable. The in-person shift requirement is central to the model's effectiveness and acceptability. Further investment is needed to train and resource local nurses who play an integral role in providing virtual medical care.

目的:探讨临床医生在为新南威尔士州西部农村和偏远医院服务的混合虚拟医疗模式中提供、促进和潜在影响的经验。设计、设置、参与者:在2022年4月7日至2023年3月16日期间,对在新南威尔士州西部地方卫生区内提供虚拟农村全科医生服务(VRGS)的农村全科医生、当地现场工作人员和当地全科医生访问医疗官员(GP VMOs)进行了采用半结构化焦点小组和个人访谈的定性研究。主要结果测量:基于定性内容分析的临床医生经验模型的关键主题和改进经验的建议。结果:对12名VRGS医生、25名现场护理人员和9名GP vmo进行了访谈。临床医生对VRGS非常积极,认为它提供了高质量的护理,是解决农村劳动力挑战的创新和可转化的解决方案。VRGS医生,特别是当地的现场工作人员,对团队建设、技能培养和增加VRGS医生对当地情况的了解非常重视。VRGS模式依赖于护士的可用性和技能,并给护士带来额外的工作量。偏远地区的护士非常重视VRGS提供的临床支持。总体而言,大多数GP vmo重视VRGS提供的疲劳缓解;然而,一些人认为VRGS削弱了当地医生的自主权和他们职位的可行性。结论:混合VRGS模式可为患者提供高质量的医疗服务,并可提高提供者的工作满意度,为临床医生所广泛接受。这项服务支持当地卫生工作人员,使农村医疗职位更具吸引力和可持续性。亲自轮班的要求是模型有效性和可接受性的核心。需要进一步投资培训在提供虚拟医疗服务方面发挥不可或缺作用的当地护士,并为她们提供资源。
{"title":"Clinician experiences of a hybrid virtual medical service supporting rural and remote hospitals: a qualitative study","authors":"Anna E Thompson,&nbsp;Emily Saurman,&nbsp;Shannon Nott,&nbsp;Andrew Wilson,&nbsp;Tim Shaw","doi":"10.5694/mja2.52525","DOIUrl":"10.5694/mja2.52525","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To explore the experiences of clinicians delivering, facilitating, and potentially affected by a hybrid virtual medical model servicing rural and remote hospitals in western New South Wales.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, setting, participants</h3>\u0000 \u0000 <p>Qualitative study using semi-structured focus groups and individual interviews, conducted between 7 April 2022 and 16 March 2023, with rural generalist doctors delivering the Virtual Rural Generalist Service (VRGS) within the Western NSW Local Health District, local site staff, and local general practitioner visiting medical officers (GP VMOs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main outcome measures</h3>\u0000 \u0000 <p>Key themes in clinician experience of the model and recommendations for improved experience, based on qualitative content analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We interviewed 12 VRGS doctors, 25 site nursing staff and nine GP VMOs. Clinicians were overwhelmingly positive about the VRGS, seeing it as providing good quality care and being an innovative and translatable solution to rural workforce challenges. In-person site visits by VRGS doctors were highly valued, especially by local site staff, for team building, skill building and increasing VRGS doctors’ understanding of the local context. The VRGS model relies on nursing availability and skill, and creates additional workload for nurses. Nurses in isolated sites valued the clinical support provided by the VRGS. Overall, most GP VMOs valued the fatigue relief offered by the VRGS; however, some viewed the VRGS as diminishing local doctors’ autonomy and the viability of their positions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The hybrid VRGS model is widely accepted by clinicians as providing good quality care for patients and high job satisfaction for providers. The service supports the local health workforce and makes rural medical positions more attractive and sustainable. The in-person shift requirement is central to the model's effectiveness and acceptability. Further investment is needed to train and resource local nurses who play an integral role in providing virtual medical care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S11","pages":"S16-S21"},"PeriodicalIF":6.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1